Mirum Pharmaceuticals Inc. (MIRM) on Monday said the primary endpoint was met in the Phase 2b portion of its AZURE-1 study evaluating brelovitug for the treatment of chronic hepatitisdelta virus (HDV).
At Week 24, brelovitug showed strong antiviral activity, with 100% of patients in the 300 mg weekly group and 75% in the 900 mg every four weeks group achieving a virologic response. The primary composite endpoint—virologic response along with normalization of liver enzyme ALT—was achieved in 45% and 35% of patients in the respective dose groups, compared with none in the delayed treatment group.
The company said treatment was well tolerated, with continued reductions in viral levels and liver enzyme markers observed over 24 weeks, supporting brelovitug's potential as a standalone therapy to treat HDV.
Mirum shares closed at $91.49 on Friday, down 0.50%.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.